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The aim o t t h i s s~u d y was to diagnose Neonatal S e p~i c c~~n i~ by d c t c m i n i n g serum p r a l b m i n l e v e l s a s a negative a c u l e 111wse r e a c t a n t ard serum 02 microglobulin conccntrationr;, a q u e s t i o~w b l e acute ~h a s e r e a c t a n t . Twenty healthy 11ewbo1.11 b;lbics a s the c o n t r o l group and 22 term newborn babies wirh s e l~t~c e m i a were i n c l u d e d i n t h e study. Serum c m c e n t r a t i o n o f realbu bum in showed a s i g n i f i c a n t (p < 0,001) decrease i n t k s e p s i s group compared with the c o n t r o l group. I t had a s e n s i v i t y r a t e or % 85, s p e c i f i t y r a t e of X 95, p o s i t i v e p r e d i c t i v e valuc of 04 eld n e g a t i v e p r e d i c t i v e v a l u e of X 91. Serum 62-microglobuli~l levels were s i~n i t i c a n t l y ( p < 0,001) higher i n the s e p s i s group Lhan i l l Lllc c o n t r o l group, yet i t llad lower s c n s i v i t y , s p e c i f i t y ar~d p o s i t i v e , lnegative p r e d i c t i v e values unnpared with Ule I:renlb~a~nin values, r e s p e c t i v e l y X 65, % 90, X 8 6 and X 72. Since scrum preal bumin assay is an e a s i l y -e s t a b l islic(1 and r e l i s b l c t c s L, we conclude Llna t %run! prealbumin determination can be m i~~i p o r L a~~t a i t i n the d i a g n o s i s of neonatal septicemia.
BENZATHINE PENICILLIN I N ALVEOLAR LOUAR AND SEGMENTAL PNEUMONIA: a c o n t r o l l e d c l i n i c a l t r i a l ( * ) Paulo Camargos.Mark Cuimaraes.Cid F e r r e i r a ( s p n . b y Prof.
114 G. Duc),Universidade Federal de Minac C e r a i s , B r a z i l .
O b j e c t i v e : t o a s s e s s t h e e f f i c a c y of benzathine p e n i c il l i n ( U P ) f o r t r e a t i n g presumedly pneumococcal a l v e o l a r l o b a r l s e g m e n t a l pneumonia(ALSP)as compared t o procaine p e n i c i l l i n ( P P ) , i n Belo Horizonte, Minas C e r a i s S t a t e , I % r a z i l . Methods: c r i t e r i a i n c l u s i o n were a)2-12 y e a r s o l d , b ) c l i n i c a l and r a d i o l o g i c a l d i a g n o s i s of ALSP,c)no p r i o r a n t i b i o t i c and d)no sev e r e concomitant disease.The BP and PP t r e a t m e n t s were randomized i n two groups and t h e regimens were one s l n g l e dose of Bl' and scven days of PP.Efficacy was assessed by c l i n i c a l and r a d i o l o g i c a l improvement i n t h e 7 t h and/or 14th day a f t e r admission.'l'he i n t e rp r e t a t i o n of c h e s t f i l m s were made i n a b l i n d n e s s f a s h i o n . S t a t i st i c a l a n a l y s i s included t h e F i s c h e r ' s Exact Test(sign.lcvcl:.OS). Results:116 p a t i e n t s had been included i n the study;63(54,3Z)were a l l o c a t e d t o BP and 53(45,7%)to PP groups. 90,5% of the p .~t i e n t s i n t h e BP group and 94.3% i n t h e PP group presented c l i n i c a l and r a d i o l o g i c improvements(p=.505). Conc1usions:a)BP treatment was a s e f l i c a c i o u s a s 1' 1' trcntnicnt f o r ALSP i n t h i s study;b)due t o high morbidity and m o r t a l i t y 01 pncumonia i n the Third World,the low c o s t and excellent compli;~ncc o f B P , t h i s regimen may be an important a l t c r n a t l v e f o r internationall y accepted PP regimen;c)more p r e c i s e e s t i m a t e s with improved pow e r w i l l be generated by higher numbers a s t h e study c o n t i n u e s . *supported by FINEP(Studies and P r o j e c t s Financing Agcncy),Urazil 'Chere is a sufficient amount of data that TNF-alpha, the monokine r d u c e d by m a c r o~h ? g e s after bacterial stimulation mi lht be a n import:tnt actor responsible o r trreverstble tlssue damage durin hlc septic shock. In a n attempt t o elucidate the ossible function of ~~l : -; h~h a in the p;tthomechanism of sepsis t k aisesment of TNF-alplta activity in thc blood of newborns with bacterial sepucaemla was performed. A sample of 21 newbortts with se sis 1 3 with Staph.epi., 1 with Steph.aur., 7 with G(-) bacteria) was slt!fied.(A group of 22 infection-free tnf;tots m:ttchcd by gestational age, birthweight and sex, were used a s a controls. TNF-alpha in the blood was determinetl by ELlSA method. For statistic analysis a nonparametric (Wilcoxon) test was used. our earlier studies (1) ketoconazole (keto), an oral antifungal agent, proved not to he useful in preterns. The atsorption of keto was probably prevent4 due to a combination of low gastric acidity and continuous gavage feeding. We now invgtigated the bioavailability of itraamazole (itra), also an oral antif* agent with tread spectrum activity and low toxicity, in pretenn infants with a ~p t i o n a l age helow 32 weeks. Traqh and peak serum levels of itra (R.51211) and its metabolite (R63373) were measured in 5 pretenn infants 48h after initiating therapy with a dose of 5rgp.g of itra in hydroxypmpyl-heta-cycl~in solution by HPLC-assay. itra
R63373
trourPl level(ng/ml) 28-264 85-588 peak level (ng/ml)
129-547 178-660
We m l u d e that ( 2 ) The effects of cbz-leucinc-tyrosine-chloromethylketone(zLYCK). an inhibitor of chymotrypsin, were investigated in the activation pathways of human neutrophil respiratory burst. At 10 pM zLYCK showed a parallel inhib~tion of superoxide productio~i stimulated with the chemoattractant lormyl-methionyi-leucyl phenylalanine (FMLP) and chymotrypsin-like activity of human neutrophils. By contrast superoxide production induced by phorbol mirystate acetate (PMA) was minimally affected by zLYCK. The known transduction pathways triggered by FMLP were analyzed. zLYCK did not affect either FMLP-induced cylosolic free calcium transient, inositoi 1.4.5 lriphosphate formation nor the PMA-induced phospholylation of the 47 kD substrate of protein kinase c. zLYCK did not allect the activity of protein kinase c extracted from neutrophds. The activity of the NADPH oxidase tested with active membranes from stimulated neutrophils or in a cell-free-system was not inhibited by zLYCK We conclude that 1) zLYCK inhibits superoxide production through the inhibition of a chymotrypsin-like protease of the neutrophil 2) zLYCK inhibits FMLP-induced activation of NADPH oxidase through a pathway independent of PtdlnsP breakdwon and cylosolic free calciulil 3) zLYCK may prove an useful pr&e for the characterization ol its target protease in neutrophil activation. Jean-Daniel Daumgartner, Fran~ois Beaufils. Francis Leclerc Georges E. Grau JS Study Group, Susanne Suter and Michel 'P. Glauser. (spn by'Luc Paunier). Dept of Pediatrics. University of Geneva, Geneva. Switzerland. lmmunotherapy with serum obtained from immunized volunteers with Escherichia Coli JS vaccine was shown to decrease the mortality from Gramnegative shock. We analyzed the effect of anti-JS plasma on the course and mortality of severe infectious purpura. Patients with a clinical diagnosis of sepsis wiwth purpuric lesions were enrolled if they were in shock. They received either anti-J5 plasma or control plasma. Before the administration of the plasma. 6 hours after and arter 5 days of evolution, serum levels of antiLJ5 antibodies. tumor necrosis factor alpha (TNF), interleukin-6 (1L-6) and elastase-al-antiprotease complexes were determined. 73 patients were randomized, 40 in the anti-J5 and 33 in the control group. Clinical and biological risk factors were similar in the two groups. However. TNF serum concentrations were 974t173pg/ml versus 473+8Spg/ml. (p=0.023) and IL-6 serum concentrations were 129+45 versus 19tSng/ml. (p=0.005) in the control group and in the treated group respectively. The duration or hypotension, of vasopressor therapy and of respiratory assistance and the occurrence of systemic complications were similar in the 2 groups. The mortality rate was 36 % ,in the control group and 25% in the treated group (p=0.317). (risk rat10:0.58;95% conridence interval:0.19-1.79). This trend disappeared after correction for imbalances at randomization using a logistic regression model. Anti-JS plasma did not change the course and the mortality of severe infectious purpura in children.
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